Transaction DateRecipientSharesTypePriceValue
15th December 2020Davis Jerel9,497Other acquisition or disposition$0.00
15th December 2020Davis Jerel285,217Other acquisition or disposition$0.00
15th December 2020Davis Jerel21,707Other acquisition or disposition$0.00
15th December 2020Davis Jerel8,579Other acquisition or disposition$0.00
9th December 2020Eric Dobmeier2,000Open or private purchase$13.08$26,150.00
8th December 2020Eric Dobmeier2,000Open or private purchase$13.24$26,483.40
23rd November 2020Srinivas Akkaraju500,000Grant/award etc.$10.00$5,000,000.00
11th November 2020Eric Dobmeier2,500Open or private purchase$13.75$34,375.00
10th November 2020Eric Dobmeier2,000Open or private purchase$13.86$27,720.00
5th October 2020Eric Dobmeier46,337Grant/award etc.$0.00
Aduro Bio Tech
Aduro Bio Tech logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 4/10.

Aduro BioTech, Inc. is a clinical-stage immunotherapy company. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD. The company's platforms stimulate and/or regulate innate and adaptive immune responses.

Ticker: ADRO
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1435049
Employees: 96
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $71 M (0%)
Marketable Securities, Current: $100 M (-35%)
Assets, Current: $181 M (-16%)
Property, Plant and Equipment, Net: $22 M (0%)
Assets: $265 M (-8%)
Accounts Payable, Current: $1 M (223%)
Liabilities, Current: $20 M (-6%)
Other Liabilities, Noncurrent: $753 Th (-19%)
Liabilities: $219 M (-3%)
Common Stock, Value, Issued: $8 Th (0%)
Common Stock, Shares, Issued: $81 M (0%)
Additional Paid in Capital, Common Stock: $557 M (0%)
Retained Earnings (Accumulated Deficit): $511 M (4%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $439 Th (6%)
Stockholders' Equity (Parent): $47 M (0%)
Liabilities and Equity: $265 M (-8%)
Revenue: $6 M (-71%)
Research and Development: $11 M (-58%)
General and Administrative Expenses: $9 M (-45%)
Restructuring Charges: $2 M (0%)
Operating Income/Loss: $17 M (-45%)
Other Income, net: $385 Th (-70%)
Provision for income taxes: $6 M (0%)